Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration

Respiratory Research

Volumn 6, Issue , 2005, Pages

  Pullamsetti, Soni ^a   Krick, Stefanie ^a   Yilmaz, Hüseyin ^a   Ghofrani, Hossein Ardeschir ^a   Schudt, Christian ^b   Weissman, Norbert ^a   Fuchs, Beate ^a   Seeger, Werner ^a   Grimminger, Friedrich ^a   Schermuly, Ralph Theo ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b ALTANA Pharma   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; GENOMIC DNA; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MONOCROTALINE; NEUTROPHIL COLLAGENASE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; SERINE PROTEINASE INHIBITOR; STROMELYSIN 2; STROMELYSIN 3; TOLAFENTRINE; UNCLASSIFIED DRUG; NAPHTHYRIDINE DERIVATIVE;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MEDIA; ARTICLE; BLOOD VESSEL FUNCTION; BLOOD VESSEL WALL; CAPILLARY RESISTANCE; CARDIOPULMONARY HEMODYNAMICS; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DISEASE SEVERITY; DNA MICROARRAY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC CODE; HEART OUTPUT; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; IN VITRO STUDY; INJECTION; LUNG BLOOD VESSEL; MALE; MOLECULAR BIOLOGY; NEBULIZATION; NONHUMAN; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; RAT STRAIN; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; THICKNESS; UPREGULATION; VASODILATATION; ANIMAL; CELL MOTION; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; HYPERTENSION, PULMONARY; INHALATIONAL DRUG ADMINISTRATION; PATHOLOGY; ULTRASTRUCTURE;

ADMINISTRATION, INHALATION; ANIMALS; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; MYOCYTES, SMOOTH MUSCLE; NAPHTHYRIDINES; RATS;

EID: 27844600662     PISSN: 1465993X     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-6-128     Document Type: Article

References (44)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
2. Archer S, Rich S: Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 2000, 102:2781-2791.
3. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994, 75:539-545.
4. Strauss BH, Robinson R, Batchelor WB, Chisholm RJ, Ravi G, Natarajan MK, Logan RA, Mehta SR, Levy DE, Ezrin AM, Keeley FW: In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res 1996, 79:541-550.
5. Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, Lafuma C, Harf A, Adnot S, Dortho MP: Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 2001, 18:838-845.
6. Qin Y, Zhou A, Ben X, Shen J, Liang Y, Li F: All-trans retinoic acid in pulmonary vascular structural remodeling in rats with pulmonary hypertension induced by monocrotaline. Chin Med J (Engl) 2001, 114:462-465.
7. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M: Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000, 6:698-702.
8. Zaidi SH, You XM, Ciura S, Husain M, Rabinovitch M: Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 2002, 105:516-521.
9. Giannelli G, Iannone F, Marinosci F, Lapadula G, Antonaci S: The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin 2005, 21:327-332.
10. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W, Grimminger F: Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004, 169:39-45.
11. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, Schudt C, Ermert L, Seeger W, Grimminger F: Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004, 94:1101-1108.
12. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75:725-748.
13. Manganiello VC, Murata T, Taira M, Belfrage P, Degerman E: Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 1995, 322:1-13.
14. Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA, Kneussl M, Grimminger F: Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:68S-72S.
15. Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA, Kneussl M, Grimminger F: Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:68S-72S.
16. Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, Grimminger F, Seeger W, Walmrath D: Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 2000, 292:512-520.
17. Schermuly RT, Krupnik E, Tenor H, Schudt C, Weissmann N, Rose F, Grimminger F, Seeger W, Walmrath D, Ghofrani HA: Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med 2001, 164:1694-1700.
18. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002, 30:2489-2492.
19. Huxtable RJ: Activation and pulmonary toxicity of pyrrolizidine alkaloids. Pharmacol Ther 1990, 47:371-389.
20. Rosenberg HC, Rabinovitch M: Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 1988, 255:H1484-H1491.
21. Kato S, Sugimura H, Kishiro I, Machida M, Suzuki H, Kaneko N: Suppressive effect of pulmonary hypertension and leukocyte activation by inhaled prostaglandin E1 in rats with monocrotaline-induced pulmonary hypertension. Exp Lung Res 2002, 28:265-273.
22. Nagaya N, Okumura H, Uematsu M, Shimizu W, Ono F, Shirai M, Mori H, Miyatake K, Kangawa K: Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am J Physiol Heart Circ Physiol 2003, 285:H2125-H2131.
23. Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W: Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension. Am J Respir Crit Care Med 2005, 172:358-363.
24. Schermuly R, Schmehl T, Gunther A, Grimminger F, Seeger W, Walmrath D: Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury. Impact on gas exchange. Am J Respir Crit Care Med 1997, 156:445-453.
25. Schermuly RT, Ghofrani HA, Enke B, Weissmann N, Grimminger F, Seeger W, Schudt C, Walmrath D: Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 1999, 160:1500-1506.
26. Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, Kummer W, Bohle RM: Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 1998, 4:1329-1333.
27. Irani C, Goncharova EA, Hunter DS, Walker CL, Panettieri RA, Krymskaya VP: Phosphatidylinositol 3-kinase but not tuberin is required for PDGF-induced cell migration. Am J Physiol Lung Cell Mol Physiol 2002, 282:L854-L862.
28. Olschewski H, Olschewski A, Rose F, Schermuly R, Schutte H, Weissmann N, Seeger W, Grimminger F: Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 2001, 138:287-297.
29. Olschewski H, Rose F, Grunig E, Ghofrani HA, Walmrath D, Schulz R, Schermuly R, Grimminger F, Seeger W: Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med 2001, 138:367-377.
30. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW: Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000, 102:3130-3136.
31. Phillips PG, Long L, Wilkins MR, Morrell NW: cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 2005, 288:L103-L115.
32. Hsieh CC, Lau Y: Migration of vascular smooth muscle cells is enhanced in cultures derived from spontaneously hypertensive rat. Pflugers Arch 1998, 435:286-292.
33. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG: Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994, 75:41-54.
34. Johnson JL, van Eys GJ, Angelini GD, George SJ: Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein. Arterioscler Thromb Vasc Biol 2001, 21:1146-1151.
35. Yang GY, Yao JS, Huey M, Hashimoto T, Young WL: Participation of P13K and ERK1/2 pathways are required for human brain vascular smooth muscle cell migration. Neurochem Int 2004, 44:441-446.
36. Horio T, Kohno M, Kano H, Ikeda M, Yasunari K, Yokokawa K, Minami M, Takeda T: Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Circ Res 1995, 77:660-664.
37. Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R, Krebs EG: Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci U S A 1993, 90:10300-10304.
38. Bomfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R: Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994, 93:1266-1274.
39. Rabinovitch M: Investigational approaches to pulmonary hypertension. Toxicol Pathol 1991, 19:458-469.
40. Tozzi CA, Poiani GJ, Harangozo AM, Boyd CD, Riley DJ: Pressure-induced connective tissue synthesis in pulmonary artery segments is dependent on intact endothelium. J Clin Invest 1989, 84:1005-1012.
41. McCawley LJ, Li S, Benavidez M, Halbleib J, Wattenberg EV, Hudson LG: Elevation of intracellular cAMP inhibits growth factor-mediated matrix metalloproteinase-9 induction and keratinocyte migration. Mol Pharmacol 2000, 58:145-151.
42. Peracchia F, Tamburro A, Prontera C, Mariani B, Rotilio D: cAMP involvement in the expression of MMP-2 and MT-MMP1 metalloproteinases in human endothelial cells. Arterioscler Thromb Vasc Biol 1997, 17:3185-3190.
43. Takahashi N, Tetsuka T, Uranishi H, Okamoto T: Inhibition of the NF-kappaB transcriptional activity by protein kinase A. Eur J Biochem 2002, 269:4559-4565.
44. Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, Ogihara T: Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther 2001, 8:1635-1642.